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A B S T R A C T
We have generated an induced pluripotent stem cell (iPSC) line KCLi001-A (iOP118) from a female atopic dermatitis (AD) patient, heterozygous for the loss-of-
function mutation c.2282del4 in the ﬁlaggrin gene (FLG). Epidermal keratinocytes were reprogrammed using non-integrating Sendai virus vectors. The entire process
of derivation and expansion of AD-iPSCs were performed under xeno-free culture conditions. Characterization of KCLi001-A line included molecular karyotyping,
mutation screening using restriction enzyme digestion and Sanger sequencing, while pluripotency and diﬀerentiation potential were conﬁrmed by expression of
associated markers in vitro and by in vivo teratoma assay.
Resource table
Unique stem cell line
identiﬁer
KCLi001-A
Alternative name(s) of
stem cell line
iOP118
Institution King's College London, London UK
Contact information of
distributor
Dusko ILIC, dusko.ilic@kcl.ac.uk
Type of cell line iPSC
Origin Human
Additional origin info Sex: Female
Ethnicity: Caucasian
Cell source Epidermal keratinocytes
Clonality Clonal
Method of
reprogramming
Non-integrating SeV-mediated delivery of
OCT4, SOX2, c-MYC and KLF4
Genetic modiﬁcation None
Type of modiﬁcation N/A
Associated disease Atopic dermatitis (AD) or eczema, OMIM
#605803
Gene/locus Filaggrin gene (FLG), loss-of-function
mutation NM_002016.1:c.2282del4
Method of
modiﬁcation
N/A
Name of transgene or
resistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock
date
December 2017
Cell line repository/
bank
N/A
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Resource utility
Generation of a library of human iPSC lines with the most common
variants in the FLG gene can be eﬃciently used to construct highly
speciﬁc in vitro 3D skin models (Petrova et al., 2014) for drug discovery
towards novel personalized therapies in AD.
Resource details
AD or eczema is an incurable, non-contagious, extensive in-
ﬂammatory and extremely pruritic chronical cutaneous disorder. AD is
one of the most common skin diseases which aﬀects up to 20% of
children and approximately 3% of adults worldwide, while its
(caption on next page)
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prevalence is continuously increasing, particularly in underdeveloped
countries (Asher et al., 2006). Several loss-of-function mutations within
FLG exon 3, including c.2282del4 variant, are considered to be the most
signiﬁcant risk factors for atopic dermatitis in the European population
(Palmer et al., 2006). The epidermal keratinocytes derived from a fe-
male AD patient who is heterozygous for c.2282del4, were repro-
grammed into iPSCs following previously established protocol with
genome non-integrating Sendai virus (SeV) vectors (Miere et al.,
2016a). Three weeks post-transduction colonies with a typical mor-
phology of pluripotent stem cells appeared and were selected to es-
tablish feeder-free iPSC clones (Fig. 1A). After ten passages, the elim-
ination of the SeV vectors was conﬁrmed in the KCLi001-A cell line by
RT-PCR using speciﬁc primers (Fig. 1B). The clones were screened with
restriction enzyme digestion and we have veriﬁed that the AD-related
mutation (NM_002016.1:c.2282del4) was retained in the iPSCs. This
ﬁnding was also conﬁrmed independently by Sanger sequencing
(Fig. 1C). Endogenous expression of pluripotency-related molecular
markers (TRA-1-60, TRA-1-81, OCT4, NANOG) in the iPSCs was as-
sessed by double immunoﬂuorescence technique (Fig. 1D). Further-
more, undiﬀerentiated colonies were also positive for alkaline phos-
phatase (AP) (Fig. 1D). Diﬀerentiation capacity of the KCLi001-A cells
into three germ layers was determined by speciﬁc immunoﬂuorescence
staining of AFP (liver, endoderm), ACTA2 (cardiac muscle, mesoderm),
and TUBB3 (neurons, ectoderm) in vitro (Fig. 1E), as well as in vivo
through a teratoma formation assay. All three germ layers, ectoderm,
mesoderm, and endoderm, were present in the teratoma, as demon-
strated by immunohistochemical analysis (Fig. 1F).
Since our aim is to use the line for modeling AD in vitro, we tested
diﬀerentiation of the KCLi001-A iPSCs into epidermal keratinocytes
(Petrova et al., 2014). The cells expressed keratinocyte-speciﬁc markers
- keratins 14 and 18 (KRT14, KRT18), and isoform of TP63 known as
ΔNp63 within three weeks in culture as expected (Fig. 1G).
Examination of the genomic integrity of our AD-iPSC line using
array CGH after more than twenty passages showed a normal female
karyotype (46, XX), whereas smaller imbalances have not been ex-
cluded (submitted in archive with journal). Taken together, these re-
sults prove that we have successfully produced a stable AD patient
speciﬁc iPSC line which can provide a powerful tool for: 1) developing
the ﬁrst iPSC-derived 3D in vitro AD-human skin equivalents (HSE); 2)
deciphering the molecular mechanisms of the disease; 3) innovative
drug screening platform in atopic dermatitis. (Table 1).
Fig. 1. Characterization of KCLi001-A line. A, The colonies display typical morphology of pluripotent stem cells under feeder-dependent and feeder-free conditions.
B, The absence of 181 bp positive SeV band at 45 and 60 days of culture indicates that the cells are SeV free. β-actin 455 bp band serves as an internal control. C, The
line is heterozygous for c.2282del4 mutation in FLG as indicated with restriction enzyme digestion and Sanger sequencing of PCR product spanning the mutation site.
Mutation generates a site for DraIII that is not present in wildtype allele. The enzyme digestion cuts 811 bp product in mutated allele into 667 bp and 134 bp, whereas
811 bp remains intact in wildtype. hESC line KCL038 is used as a negative control. D, Pluripotency markers. Alkaline phosphatase activity (AP) was restricted to the
iPSC colony (green) growing on AP-negative feeder cells. Both iPSC colony and feeders are positive for actin (phalloidin) staining (red). iPSC colonies are positive for
POU5F1 (red), TRA-1-81 (green), NANOG (red) and TRA-1-60 (green) pluripotency markers. E, Spontaneous diﬀerentiation in vitro. The cells can diﬀerentiate into
all three germ layers as demonstrated with markers speciﬁc for ectoderm (TUBB3), endoderm (AFP) and mesoderm (ACTA2). Nuclei are visualized with Hoechst
33342. F, Spontaneous diﬀerentiation in vivo. Gross anatomy and staining for human-speciﬁc MTCO2 marker iPSC indicated that the teratoma is incapsulated and
did not invade surrounding tissues. Teratoma contained cells from all three germ layers as demonstrated with markers speciﬁc for ectoderm (TUBB3, GFAP),
endoderm (AFP, GATA4) and mesoderm (AB-PAS, DESMIN). G, Directed diﬀerentiation into keratinocytes. The cells expressed keratinocyte-speciﬁc markers KRT14,
KRT18, TP63 (ΔNp63) in time-dependent manner.
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Light microscopy hESC-like morphology (compact, dense, roundly shaped colonies with
sharp edges, high nucleus to cytoplasm ratio)
Fig. 1 panel A
Phenotype Qualitative analysis (Immunoﬂuorescence
staining and AP activity)
Expression of pluripotency- markers TRA-1-60, TRA-1-81, OCT4, NANOG;
AP-positive
Fig. 1 panel D
Quantitative analysis (immunoﬂuorescence
counting)
Percentage of cells positive for pluripotent markers: OCT4–94%, NANOG –
95, TRA-1-60: 95%, TRA-1-81: 93%
Fig. 1 panel D
Genotype Array CGH 46, XX Submitted in archive with
journal
Identity STR analysis DNA ﬁngerprinting PCR, 17 speciﬁc markers tested Submitted in archive with
journal
Mutation analysis Sequencing Heterozygous, c.2282del4 in exon 3 of FLG
hESC line KCL038 (Miere et al., 2016b) is used as wild-type control.
Fig. 1 panel C
Restriction enzyme digestion Mutation 2282del4 creates a new DraIII site, which was used to screen
short, highly speciﬁc PCR fragments for this variant.
hESC line KCL038 (Miere et al., 2016b) is used as wild-type control.
Fig. 1 panel C
Microbiology and
virology
Mycoplasma LookOut Mycoplasma PCR Detection Kit: negative (Supplementary ﬁle 1) Supplementary Fig. 1
Diﬀerentiation potential Embryoid body formation Expression of smooth muscle actin (ACTA2), α-fetoprotein (AFP) and βIII-
tubulin (TUBB3)
Fig. 1 panel E
Teratoma formation Alcian blue/periodic acid Schiﬀ (PAS)-stained cartilage and desmin for
mesoderm, TUBB3 and glial ﬁbrillary acidic protein (GFAP) for ectoderm,
and GATA4 and AFP for endoderm, while mitochondrially encoded
cytochrome C oxidase II (MTCO2) only immunostains human
mitochondria in the cells of the teratoma
Fig. 1 panel F
Directed diﬀerentiation into keratinocytes The iPSC-derived keratinocytes expressed the epithelial cell markers:
KRT14, KRT18, and isoform of TP63 (ΔNp63)
Fig. 1 panel G
Donor screening HIV 1+2 Hepatitis B, Hepatitis C Not tested N/A
Genotype additional
info
Blood group genotyping Not tested N/A
HLA tissue typing Not tested N/A
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Materials and methods
Epidermal keratinocytes reprogramming
Patient keratinocytes of passage 3 were transduced with genome
integration-free SeV virus kit (CytoTune 2.0, Life Technologies) as de-
scribed (Miere et al., 2016a). Clonal selection of fully reprogrammed
cells was performed manually by picking individual clones with hESC-
like appearance (Table 1). The iPSCs under feeder-free culture condi-
tions were maintained on Matrigel (BD Biosciences) in TeSR2 medium
(STEMCELL Technologies).
FLG mutation veriﬁcation
Genomic DNA was extracted from KCLi001-A cells using DNeasy
Blood & Tissue Kits (Qiagen) and samples were veriﬁed independently
by restriction enzyme digestion and Sanger sequencing using the pri-
mers described in Table 2. A 311 bp sequence in exon 3 of FLG was
ampliﬁed and Euroﬁns Genomics provided DNA sequencing service.
Mutation c. 2282del4 creates a new DraIII site, which was used to
screen short, highly speciﬁc 811 bp FLG gene fragment, as described in
more detail previously (Palmer et al., 2006).
Reverse transcription PCR analysis of SeV vectors
Total RNA was isolated from the cells 7, 45 and 60 days post-
transduction (RNeasy mini Kit, Qiagen). SeV speciﬁc primers were used
to assess the presence of remaining Sendai virus vectors (Table 2). RT-
PCR for the detection of SeV transgenes was carried out using the Su-
perScript IV First-strand cDNA synthesis reaction kit (Invitrogen).
Pluripotency markers
The pluripotency status of KCLi001-A line was evaluated by im-
munostaining for three germ layer markers in spontaneously diﬀer-
entiated cells (Table 1) as previously described (Petrova et al., 2014).
Alkaline phosphatase activity
Emerging iPSCs were analyzed for alkaline phosphatase activity by
AP Live Stain (Thermo Fisher). After live staining, iPSCs were washed
and ﬁxed, and cytoskeletal actin ﬁlaments have been contrasted by
labelling with rhodamine phalloidin (Molecular Probes).
Spontaneuous diﬀerentiation into three germ layers
To test the diﬀerentiation capacity of our iPSC line, in vitro em-
bryonic body formation, as well as in vivo conventional teratoma assay
were assessed (Table 1), as previously described (Petrova et al., 2014).
Directed diﬀerentiation into keratinocytes
KCLi001-A were diﬀerentiated into keratinocytes following mod-
iﬁed protocol Petrova et al. (2014). Brieﬂy, the iPSC diﬀerentiation was
initiated on Vitronectin XF (STEMCELL Technologies)-coated surface in
deﬁned keratinocyte-serum-free medium (DKSFM, Gibco) supple-
mented with 1 μM all-trans retinoic acid (ATRA; Sigma-Aldrich) and
10 ng/μl bone morphogenetic protein 4 (BMP4; R&D System). Diﬀer-
ential expression of the lineage-speciﬁc markers was assessed at Day 7,
14 and 21 of the protocol with immunostaining (Table 1).
Molecular karyotyping
Array comparative genomic hybridization (aCGH) and short tandem
repeat (STR) analysis of 17 STR loci were conducted at Viapath
Genetics Centre.
Mycoplasma contamination detection
The absence of mycoplasma contamination was detected using
LookOut® Mycoplasma PCR Detection Kit (Sigma-Aldrich).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.07.014.
Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Class Antibody Dilution Company Cat # and RRID
Pluripotency Markers Mouse anti-TRA-1-60 1:100 Millipore Cat# MAB4360, RRID: AB_2119183
Goat anti-NANOG 1:100 R&D Cat# AF1997, RRID: AB_355097
Mouse anti-TRA-1-81 1:100 Millipore Cat# MAB4381, RRID: AB_177638
Mouse anti-OCT4 1:100 SantaCruz Biotech.; Cat. No. SC-5279, RRID: AB_628051
Diﬀerentiation markers Mouse anti-AFP 1:100 Sigma Cat# A8452, RRID: AB_258392
Mouse anti-ACTA2 1:100 Sigma Cat# A5228, RRID: AB_262054
Mouse anti-TUBB3 1:100 Sigma Cat# T5076, RRID: AB_532291
Rabbit anti-KRT 14 1:1000 Abcam Cat# ab181595 RRID: N/A
Mouse anti-KRT 18 1:1000 Sigma Cat# C8541, RRID: AB_476885
Mouse anti-ΔNp63 1:100 Abcam Cat# ab172731 RRID: N/A
Mouse anti-cytokeratin, pan 1:300 Abcam Cat# ab7753, RRID:AB_306047
Mouse anti-desmin 1:150 Dako Cat# M0760, RRID:AB_2335684
Goat anti-GATA-4 1:10 R&D Systems Cat# AF2606, RRID:AB_2232177
Rabbit anti-GFAP 1:200 Dako Cat# Z0334, RRID:AB_10013382
Mouse anti-MTCO2 1:10 Abcam Cat# ab110258, RRID:AB_10887758
Secondary antibodies Donkey anti-mouse Alexa Fluor 488-conjugated
IgM
1:100 Jackson ImmunoResearch Labs Cat# 715–545-140, RRID:AB_2340845
Donkey anti-goat Rhodamine X-conjugated IgG 1:100 Jackson ImmunoResearch Labs Cat# 705–295-147, RRID:AB_2340423
Donkey anti-mouse Rhodamine-X-conjugated IgG 1:100 Jackson ImmunoResearch Labs Cat# 715–295-150, RRID:AB_2340831
Donkey anti-rabbit FITC-conjugated IgG 1:100 Jackson ImmunoResearch Labs Cat# 711–095-152, RRID:AB_2315776
Primers
Target Forward/Reverse primer (5′-3′)
Genotyping FLG AATAGGTCTGGACACTCAGGT/-GGGAGGACTCAGACTGTTT
Targeted mutation analysis/sequencing FLG CTCCAGTCAGCAGACAGCTC/-GTCTTACTCCAGTGCTGGGC
Sendai Virus checking (RT-PCR) SeV GGATCACTAGGTGATATCGAGC/-ACCAGACAAGAGTTTAAGAGATATGTATC
KOS ATGCACCGCTACGACGTGAGCGC/-ACCTTGACAATCCTGATGTGG
KLF-4 TTCCTGCATGCCAGAGGAGCCC/-AATGTATCGAAGGTGCTCAA
c-MYC TAACTGACTAGCAGGCTTGTCG/-TCCACATACAGTCCTGGATGATGATG
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